Garri Zmudze, provides a candid take on the longevity sector's future and its current misconceptions. He brings personal experience to his professional mission, aiming to transform how we approach aging and health. The investment firm champions companies innovating in consumer health, biotech, and AI-driven drug discovery. The article discusses the longevity market's growth, projected to nearly double by 2030, and LongeVC's strategic investment in technologies that promise to redefine aging and extend healthy lifespans.
Zmudze critiques the unstandardised practices in longevity clinics and stresses the significance of data-driven, evidence-based therapies. He envisions an “ageless future” through a collective of technologies, emphasising the importance of early diagnostics and a shift in health-related economic models.
LongeVC's investment approach focuses on a no-compromise attitude towards innovative potential and leadership quality. Companies such as Haut.AI and Freedom Biosciences exemplify LongeVC's portfolio, showcasing consumer applications and novel mental health treatments poised to impact the industry significantly.
For further details on Garri Zmudze's perspective on longevity, click here and read the article.
Zmudze critiques the unstandardised practices in longevity clinics and stresses the significance of data-driven, evidence-based therapies. He envisions an “ageless future” through a collective of technologies, emphasising the importance of early diagnostics and a shift in health-related economic models.
LongeVC's investment approach focuses on a no-compromise attitude towards innovative potential and leadership quality. Companies such as Haut.AI and Freedom Biosciences exemplify LongeVC's portfolio, showcasing consumer applications and novel mental health treatments poised to impact the industry significantly.
For further details on Garri Zmudze's perspective on longevity, click here and read the article.